Form 4 for ICUI ICU MEDICAL INC/DE
Accepted 2024-03-11 00:00:00 ET · period of report 2024-03-07 · accession 0001410442-24-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-03-11 | 2024-03-07+ | ICUI | Jain Vivek | COB, CEO, Dir | M - OptEx | $0.00 | +33.4K | 90.5K | +58% | $0 |
| DM | 2024-03-11 | 2024-03-07+ | ICUI | Jain Vivek | COB, CEO, Dir | F - Tax | $105.11 | -18.3K | 88.8K | -17% | -$1.92M |
| DM | 2024-03-11 | 2024-03-07+ | ICUI | Jain Vivek | COB, CEO, Dir | M - OptEx | $0.00 | -33.4K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-08 | M | A | 8,331 | $0.00 | 106,962 | D | — | — | (F2) These Securities are Performance-based Restricted Stock Units (PRSU). |
| 2 | Common | Common Stock | 2024-03-08 | F | D | 1,384 | $104.52 | 98,631 | D | — | — | |
| 3 | Common | Common Stock | 2024-03-08 | M | A | 2,525 | $0.00 | 100,015 | D | — | — | (F1) These securities are Restricted Stock Units. |
| 4 | Common | Common Stock | 2024-03-07 | F | D | 10,588 | $105.39 | 97,490 | D | — | — | |
| 5 | Common | Common Stock | 2024-03-07 | M | A | 19,306 | $0.00 | 108,078 | D | — | — | (F2) These Securities are Performance-based Restricted Stock Units (PRSU). |
| 6 | Common | Common Stock | 2024-03-08 | F | D | 4,569 | $104.52 | 102,393 | D | — | — | |
| 7 | Common | Common Stock | 2024-03-07 | M | A | 3,218 | $0.00 | 90,536 | D | — | — | (F1) These securities are Restricted Stock Units. |
| 8 | Common | Common Stock | 2024-03-07 | F | D | 1,764 | $105.39 | 88,772 | D | — | — | |
| 9 | Derivative | Common Stock | 2024-03-08 | M | D | 2,525 | $0.00 | 0 | D | $0.00 · 2022-03-08 to 2024-03-08 | 2,525 Common Stock | (F1) These securities are Restricted Stock Units. (F3) There is neither a purchase price nor an exercise price for the Restricted Stock Units. (F4) One third of the units subject to the award shall vest on each of the first, second, and third anniversaries of the grant date. (F5) These are restricted stock units that fully vest 3 years from the grant date. |
| 10 | Derivative | Common Stock | 2024-03-07 | M | D | 3,218 | $0.00 | 3,218 | D | $0.00 · 2023-03-07 to 2025-03-07 | 3,218 Common Stock | (F1) These securities are Restricted Stock Units. (F3) There is neither a purchase price nor an exercise price for the Restricted Stock Units. (F4) One third of the units subject to the award shall vest on each of the first, second, and third anniversaries of the grant date. (F5) These are restricted stock units that fully vest 3 years from the grant date. |
| 11 | Derivative | Performance Shares | 2024-03-07 | M | D | 19,306 | $0.00 | 0 | D | $0.00 · — to 2024-03-07 | 19,306 Common Stock | (F2) These Securities are Performance-based Restricted Stock Units (PRSU). (F6) There is neither a purchase price nor an exercise price for the PRSUs. (F7) These PRSUs were granted on March 7, 2022 and had a 2-year cliff-vest performance period subject to the satisfaction of performance-based metrics and continuous services through the vest date. The PRSUs were approved for vesting in February 2024 by the Compensation Committee at 200% of the original grant. |
| 12 | Derivative | Performance Shares | 2024-03-08 | M | D | 8,331 | $0.00 | 0 | D | $0.00 · — to 2024-03-08 | 8,331 Common Stock | (F2) These Securities are Performance-based Restricted Stock Units (PRSU). (F6) There is neither a purchase price nor an exercise price for the PRSUs. (F8) These PRSUs were granted on March 8, 2021 and had a 3-Year cliff-vest subject to the satisfaction of performance-based metrics and continuous services through the vest date. The PRSUs were approved for vesting in February 2024 by the Compensation Committee at 110% of the original grant. |